



August 2021

**Harbour BioMed** **Journal**  
Investor Relations

02142.HK

**HARBOUR**  
BIOMED



# CONTENTS


HBM Overview	01
Company Announcement	02
Company News	03
Myasthenia Gravis (GM)	04
HK BioMed Industry	05
Global Market Overview	06

# HBM (02142.HK)


Overview	
Website--Investor Access	<a href="https://www.harbourbiomed.com/investor">https://www.harbourbiomed.com/investor</a>
Market Cap (07/30, Mil HK\$)	7,165
Total Share Capital (Mil)	768
Circulation Stock (Mil)	768

In July, the Hong Kong stock market experienced substantial volatility with various indices falling sharply – the Hang Seng Index and the Hang Seng Composite Index closed the month by dropping 8.3% and 9.6%, respectively. The Hang Seng Healthcare Index closed the month by dropping 14.4%. HBM's share price in July was affected by the overall market performance. The closing price at the end of the month was HK \$9.33, down 2.1% from the beginning of the month while significantly outperforming the overall market.

### HBM Stock Performance – July



### The Hang Seng Composite Index (HSCI) – July



# Company Announcement

---

On July 6<sup>th</sup>, the company announced positive topline results from its phase 2 clinical trial of batoclimab (HBM9161) for generalized myasthenia gravis (MG). Data generated from the Phase 2 study, as the first clinical evidence of anti-FcRn therapies in China, showed a statistically significant and clinically meaningful efficacy of batoclimab over placebo, as well as a favorable safety and tolerability profile – it has alleviated myasthenic symptoms rapidly with satisfactory safety profile in Chinese patients, supporting batoclimab as a potential novel solution to fill the current treatment gap for MG patients.

---

On July 16<sup>th</sup>, the company announced last patient dosing in a phase 1b/2a study of its anti-FcRn antibody, batoclimab (HBM9161) for the treatment of acute neuromyelitis optical spectrum disorder (NMOSD). This clinical study aims to assess the safety, tolerability, pharmacodynamics, and efficacy of batoclimab in patients with NMOSD. It is the first global anti-FcRn study for the treatment of NMOSD.

---

On July 19<sup>th</sup>, the company was pleased to announce that it has been informed by the Icahn School of Medicine (Mount Sinai) that it has entered into an exclusive licensing agreement with a third party for a collection of its SARS-COV-2 (COVID-19) virus neutralizing antibodies. The agreement also takes into consideration that the third party may seek future collaboration in the development of fully human monoclonal antibodies for therapeutic applications. The company and Mount Sinai entered into a collaboration agreement on October 11, 2019 to develop a collection of COVID-19 virus neutralizing antibodies, under which the company is entitled to receive 25% of the revenue from Mount Sinai obtained from this licensing deal.

---

On July 26<sup>th</sup>, the company announced to release the clinical data from its Phase 1 study of next-generation anti-CTLA-4 antibody, HBM4003 at the European Society for Medical Oncology (ESMO) Congress in September 2021. This is a dose-escalating monotherapy study in the treatment of advanced solid tumors. HBM4003's preliminary clinical data demonstrates encouraging anti-tumor efficacy. The novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug. The data obtained from the study have further validated pre-clinical findings of HBM4003, which shows potent efficacy and safety profile.

---

On July 26<sup>th</sup>, the company published its 2020 Environmental, Social and Governance Report. With the mission of "focusing on core technologies, empowering industry upgrades, leading global innovation, and serving human health", the company has always adhered to the concept of corporate sustainable development – taking “green operation, sustainable development and social responsibility” as one of the strategic development goals and has been implementing it resolutely.



# Company News

01

HBM is to present phase I data on HBM4003 next-generation anti-CTLA-4 antibody in September at the 2021 ESMO Conference

02

HBM reports positive topline results from phase 2 trial of batoclimab in generalized myasthenia gravis

03

Professor Chongbo Zhao, MD, the principal investigator of batoclimab, interprets myasthenia gravis

04

HBM announces last patient dosing of phase 1b/2a study of anti-FcRn batoclimab for treating neuromyelitis optical spectrum disorder

05

HBM's fully human heavy chain only antibody platform, HCAb empowers original innovation

06

HBM appoints Yingying Chen, PhD, as Chief Financial Officer

07

HBM has successfully developed COVID-19 neutralizing antibody for the third time and benefits from recent licensing agreement

08

HBM helps launching the first China Myasthenia Gravis and Neurology Medicine Innovation Public Welfare Summit Forum


09

HBM donates RMB 1 Million to the Red Cross Foundation of China for the flood disaster in Henan province

# Myasthenia Gravis (GM)


## Positive Results from batoclimab Phase 2 Study of the Treatment of Generalized Myasthenia Gravis

On July 6<sup>th</sup>, the company announced the results of the phase 2 clinical study of batoclimab in the treatment of myasthenia gravis. The primary endpoint analysis showed that batoclimab induced rapid, substantial and persistent clinical improvement over placebo as measured by MG-ADL and QMG, the primary evaluation of the clinical treatment. All patients on treatments showed robust IgG reduction – on day 43, IgG decreased 57% and 74% from baseline in 340mg and 680mg groups, respectively.



## Myasthenia Gravis

Myasthenia gravis (MG) is a neuromuscular disease mediated by pathogenic IgG that severely affects quality of life. Patients develop auto-antibodies (IgG) that lead to an immunological attack on critical signaling proteins at the junction between nerve and muscle cells, thereby inhibiting the ability of nerves to communicate properly with muscles. This leads to muscle weakness, which can be localized to the ocular muscles, or which can be more generalized throughout the body. Patients with localized disease suffer from the mildest symptoms, including droopy eyelids and blurred or double vision due to partial paralysis of eye movements. Many patients find it difficult to perform daily activities due to both insufficient improvement in symptoms even after treatment and the long-term side effects of oral corticosteroids, a common treatment for MG. Approximately 15% to 20% of MG patients will experience at least one myasthenic crisis over their lifetimes. During myasthenic crisis, the impairment of muscles required to breathe can become life-threatening, leading to death in approximately 2% to 5% of cases.




# HK BioMed Industry

## Market Overview

In July 2021, the HSCI closed at 4,004.47, down 9.6% from the beginning of the month. The HSHCI closed at 6,797.79, down 14.4% from the beginning of the month. The China Hong Kong Biotech index (CESHKB.CSI) closed at 13,928.82, down 12.6% from the beginning of the month.

### HK Listing BioMed Companies (18A)

■ Closing Price—2021/07/02 ■ Closing Price—2021/07/30



### HK Listing BioMed Companies (18A)

	Company	Closing Price (2021.07.02)	Closing Price (2021.07.30)	Stock Price Volatility
1	Kintor	59.20	73.85	24.7%
2	Ascentage	45.35	45.55	0.4%
3	HBM	9.53	9.33	-2.1%
4	TOT	4.40	4.25	-3.4%
5	Immunotech	18.08	17.18	-5.0%
6	Mabpharm	1.24	1.17	-5.6%
7	InnoCare	27.40	25.60	-6.6%
8	SinoMab	3.47	3.17	-8.6%
9	Innovent	87.60	79.25	-9.5%
10	Beigene	205.20	183.70	-10.5%
11	Hua	4.49	4.01	-10.7%
12	Cstone	16.20	14.36	-11.4%
13	Jacobio	21.25	18.58	-12.6%
14	JW	23.40	20.45	-12.6%
15	Alphamab	24.80	21.50	-13.3%
16	Akeso	59.60	51.55	-13.5%
17	RemeGen	116.20	99.25	-14.6%
18	Henlius	38.25	32.25	-15.7%
19	TopAlliance	62.15	52.30	-15.8%
20	Ascleitis	3.51	2.93	-16.5%
21	Everest	75.00	58.90	-21.5%
22	Zai Lab	1,359.00	1,058.00	-22.1%
23	Antengene	18.56	14.30	-23.0%
24	Genor	17.38	13.32	-23.4%

# Global Market Overview

Global Market Index			
	Closing Price		
	2021.07.02	2021.07.15	2021.07.30
Dow Jones Industrial	34,786.35	34,987.02	34,935.47
Nasdaq Composite	14,639.33	14,543.13	14,672.68
UK FTSE 100	7,123.27	7,012.02	7,032.30
German DAX	15,650.09	15,629.66	15,544.39
France CAC40	6,552.86	6,493.36	6,612.76

HK Market Index			
	Closing Price		
	2021.07.02	2021.07.15	2021.07.30
Hang Seng	28,310.42	27,996.27	25,961.03
Hang Seng Composite	4,428.18	4,366.82	4,004.47
Hang Seng Tech	7892.40	7,661.25	6,780.97
HS China Enterprise	10,415.58	10,174.27	9,233.22
Hang Seng Healthcare	7,937.79	7,816.52	6,797.79

Global Economic Data – July			
Country	Related Indicator	Estimated	Actual
US	Richmond Fed Manufacturing	20	27
US	Conf Board Consumer Confidence	123.9	129.1
UK	CBI Distributive Trades	21	23
EU	Consumer Confidence Final Value	118.5	119
Germany	IFO Business Climate	102.1	100.8

- Euro zone' s initial annual rate of inflation in July rose to 2.2%, a peak in more than two and a half years.
- The US Chicago PMI unexpectedly rebounded to 73.4 in July, higher than expected.
- The growth rate of the annualized quarterly rate of US GDP' s initial value in the second quarter accelerated slightly to 6.5%, far from expectations.
- The initial value of German CPI rose to 3.8% in July, exceeding expectations.



# HARBOUR B I O M E D



Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE™) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.



Harbour BioMed

[ir@harbourbiomed.com](mailto:ir@harbourbiomed.com)  
[www.harbourbiomed.com](http://www.harbourbiomed.com)

linkedin:  
<https://www.linkedin.com/company/13244036/admin/>